SlateStone Wealth LLC Buys 1,000 Shares of Kenvue Inc. (NYSE:KVUE)

SlateStone Wealth LLC boosted its stake in Kenvue Inc. (NYSE:KVUE) by 3.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,685 shares of the company’s stock after acquiring an additional 1,000 shares during the period. SlateStone Wealth LLC’s holdings in Kenvue were worth $612,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Los Angeles Capital Management LLC bought a new position in shares of Kenvue during the 3rd quarter worth approximately $213,000. Victory Capital Management Inc. boosted its holdings in shares of Kenvue by 66.2% during the 3rd quarter. Victory Capital Management Inc. now owns 1,328,074 shares of the company’s stock worth $30,718,000 after buying an additional 528,849 shares in the last quarter. Huntington National Bank boosted its holdings in shares of Kenvue by 26.5% during the 3rd quarter. Huntington National Bank now owns 4,161 shares of the company’s stock worth $96,000 after buying an additional 871 shares in the last quarter. Metis Global Partners LLC boosted its holdings in shares of Kenvue by 1.5% during the 3rd quarter. Metis Global Partners LLC now owns 61,107 shares of the company’s stock worth $1,413,000 after buying an additional 895 shares in the last quarter. Finally, CIBC Asset Management Inc boosted its holdings in shares of Kenvue by 4.5% during the 3rd quarter. CIBC Asset Management Inc now owns 435,776 shares of the company’s stock worth $10,079,000 after buying an additional 18,778 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on KVUE. Barclays cut their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday, January 17th. Canaccord Genuity Group increased their price target on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and cut their target price for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. UBS Group cut their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday, February 7th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Kenvue has an average rating of “Hold” and a consensus target price of $23.75.

Kenvue Trading Down 1.6 %

NYSE KVUE opened at $22.81 on Monday. The firm has a market capitalization of $43.59 billion, a P/E ratio of 43.03, a PEG ratio of 2.62 and a beta of 1.25. The business has a fifty day simple moving average of $21.84 and a 200 day simple moving average of $22.39. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.60%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s dividend payout ratio is presently 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.